The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Vaccines for Seasonal and Pandemic Influenza
Abstract
Seasonal influenza continues to have a huge annual impact in the United States, accounting for tens of millions of illnesses, hundreds of thousands of excess hospitalizations, and tens of thousands of excess deaths. Vaccination remains the mainstay for the prevention of influenza. In the United States, 2 types of influenza vaccine are currently licensed: trivalent inactivated influenza vaccine and live attenuated influenza vaccine. Both are safe and effective in the populations for which they are approved for use. Children, adults <65 years of age, and the elderly all receive substantial health benefits from vaccination. In addition, vaccination appears to be cost-effective, if not cost saving, across the age spectrum. Despite long-standing recommendations for the routine vaccination of persons in high-priority groups, US vaccination rates remain too low across all age groups. Important issues to be addressed include improving vaccine delivery to current and expanded target groups, ensuring timely availability of adequate vaccine supply, and development of even more effective vaccines. Development of a vaccine against potentially pandemic strains is an essential part of the strategy to control and prevent a pandemic outbreak. The use of existing technologies for influenza vaccine production would be the most straightforward approach, because these technologies are commercially available and licensing would be relatively simple. Approaches currently being tested include subvirion inactivated vaccines and cold-adapted, live attenuated vaccines. Preliminary results have suggested that, for some pandemic antigens, particularly H5, subvirion inactivated vaccines are poorly immunogenic, for reasons that are not clear. Data from evaluation of live pandemic vaccines are pending. Second-generation approaches designed to provide improved immune responses at lower doses have focused on adjuvants such as alum and MF59, which are currently licensed for influenza or other vaccines. Additional experimental approaches are required to achieve the ultimate goal for seasonal and pandemic influenza prevention--namely, the ability to generate broadly cross-reactive and durable protection in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Influenza-Associated Hospitalizations in the United States
Thompson, W. W. (2004) · JAMA · doi:10.1001/jama.292.11.1333 · Cited by 2,213
Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review
Jefferson, T., Rivetti, D., Rivetti, A., Rudin, M., Di Pietrantonj, C., & Demicheli, V (2005) · The Lancet · doi:10.1016/s0140-6736(05)67339-4 · Cited by 601
Cited by
Phage Cocktails and the Future of Phage Therapy
Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013) · Future Microbiology · doi:10.2217/fmb.13.47 · Cited by 914
Harper, S. A., Bradley, J. S., Englund, J. A., File, T. M., Gravenstein, S., Hayden, F. G., McGeer, A. J., Neuzil, K. M., Pavia, A. T., Tapper, M. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598513 · Cited by 647
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Olsen, S. J., Karron, R. A., Jernigan, D. B., & Bresee, J. S. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6505a1 · Cited by 593
Kunisaki, K. M., & Janoff, E. N. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70175-6 · Cited by 516
Harper, S. A., Bradley, J. S., Englund, J. A., File, T. M., Gravenstein, S., Hayden, F. G., McGeer, A. J., Neuzil, K. M., Pavia, A. T., Tapper, M. L., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/604670 · Cited by 321
Metadata
- Authors
- Nichol, K. L., & Treanor, J. J.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-11
- Volume
- 194
- Issue
- s2
- Pages
- S111-S118
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2075649492
- Cited by
- 228
- References
- 2
- FWCI
- 13.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vaccines for Seasonal and Pandemic Influenza. https://app.cochat.ai/papers/10.1086/507544
- The paper
- Nichol, K. L., & Treanor, J. J. (2006). Vaccines for Seasonal and Pandemic Influenza. The Journal of Infectious Diseases. https://doi.org/10.1086/507544
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.